Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119831
Chunk: 219

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 219
---
 over 10,000 primary care physicians, pain specialists, neurologists, rheumatologist, and palliative care physicians who we believe treat the majority of PHN patients. 
 Additionally, we are utilizing direct-to-patient marketing strategies to expand awareness and utilization of ZTlido. Our managed healthcare account executives have                                                                                       
 extensive experience in negotiating contracts and have already achieved significant uptake by adding ZTlido to key formularies such as CVS Caremark/Aetna Commercial, Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial),     
 United Healthcare Commercial, Optum Rx Select Commercial, Anthem Blue Cross Blue Shield (“BCBS”), BCBS Louisiana and Kansas, Lifetime/Excellus BCBS, MedImpact, CareFirst, Elixir Commercial and Medicaid in California, Florida, Idaho, and              
 North Dakota.                                                                                                                                                                                                                                             |

| • |     | Commercialize and successfully continue launch of                                                                                                                                                                                           
 ELYXYB® for migraine in the U.S. We will utilize our current commercial infrastructure comprised of our sales, marketing and managed health care functions to promote ELYXYB for                                                            
 acute migraine to healthcare providers (“HCPs”) in the U.S. market. There is a good degree of overlap between the current Scilex sales force HCP targets and HCPs who prescribe medications for acute migraine, allowing for efficient dual 
 promotion of ELYXYB and ZTlido. The principal elements of the ELYXYB strategy are the following:                                                                                                                                            |

| • |     | Educate the market on the need for and value of a novel and differentiated option for the treatment of acute                                                                                                  
 migraine, where a high degree of unmet medical need already exists. We will leverage our in-person sales field forces, medical affairs teams, and omni-channel HCP engagement campaigns to drive awareness of 
 ELYXYB features and benefits.                                                                                                                                                                                 |

| • |     | Broaden access to ELYXYB. Our managed healthcare account executives will negotiate contracts with key payer and 
 pharmacy stakeholders to achieve uptake to key formularies.                                                     |

| • |     | Commercialize and successfully continue launch of                                                                                          
 GLOPERBA® for gout in the U.S. We will utilize our current commercial infrastructure comprised of our sales, marketing, and managed health |

138

| care functions to promote GLOPERBA® for gout to approximately 3,000 HCPs in the U.S. market. We anticipate a good degree